Broad-based strategies underpinning growth outlook

Company

21 Apr 2025 | 5 Min Read

Tushar Manudhane recommends buying Glenmark Pharma stock at INR1,342 with a target price of INR1,690, representing a 26% potential upside.

Glenmark Pharma's market capitalization is INR378.8 billion (USD4.4 billion) with a 52-week range of INR985 to INR1831.

The company is expected to achieve 11%/17%/20% sales/EBITDA/PAT CAGR over FY25-27, reaching INR164 billion/INR33 billion/INR20 billion.

The company is actively working to expand its pipeline by adding respiratory products to drive growth in the US market.

Glenmark Pharma's financials and valuations indicate a positive outlook, with a P/E ratio of 26.9, EV/EBITDA ratio of 15.8, and a dividend yield of 0.2%.

The company's strategic initiatives and focus on expanding its branded portfolio across markets support the expectation of 11% sales CAGR over FY25-27.